Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
Spunt
Sheri L
SL
St. Jude Children's Research Hospital and University of Tennessee College of Medicine, Memphis, Tennessee 38105-2794, USA. sheri.spunt@stjude.org
Smith
Lynette M
LM
Ruymann
Frederick B
FB
Qualman
Stephen J
SJ
Donaldson
Sarah S
SS
Rodeberg
David A
DA
Anderson
James R
JR
Crist
William M
WM
Link
Michael P
MP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000494:pharmacology*; D018572:Disease-Free Survival; D004317:Doxorubicin; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D020714:Maximum Tolerated Dose; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D012306:Risk; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide